Compounds > d-beta-hydroxybutyrate-(r)-1,3 butanediol monoester
Page last updated: 2024-11-13

d-beta-hydroxybutyrate-(r)-1,3 butanediol monoester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID44631890
SCHEMBL ID431832
MeSH IDM0576078

Synonyms (30)

Synonym
HY-15344
bd-acac 2
CS-0735
(r,r)-bd-acac 2
SCHEMBL431832
ketone ester
1208313-97-6
(r)-hydroxybutyl (r)-3-hydroxybutyrate ester
3'-hydroxybutyl (3r)-3-hydroxybutanoate, (3'r)-
d-beta-hydroxybutyrate ester
(r)-hydroxybutyl (r)-3-hydroxybutyrate
butanoic acid, 3-hydroxy-, (3r)-3-hydroxybutyl ester, (3r)-
unii-x587fw0372
x587fw0372 ,
d-beta-hydroxybutyrate-(r)-1,3 butanediol monoester
d-.beta.-hydroxybutyrate ester
3(r)-hydroxybutyl 3(r)-hydroxybutyrate
DTXSID20660064
(r)-3-hydroxybutyl (r)-3-hydroxybutyrate
AKOS030526321
(r)-(r)-3-hydroxybutyl 3-hydroxybutanoate
EX-A3654
AOWPVIWVMWUSBD-RNFRBKRXSA-N
(3'r)-3'-hydroxybutyl (3r)-3-hydroxybutanoate
Q27293568
AT37168
(r)-3-hydroxybutyl (r)-3-hydroxybutanoate
MS-22942
[(3r)-3-hydroxybutyl] (3r)-3-hydroxybutanoate
A903933

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" We conclude that sustained exogenous ketosis using a ketone monoester is safe and well-tolerated by healthy adults."( Safety and tolerability of sustained exogenous ketosis using ketone monoester drinks for 28 days in healthy adults.
Clarke, K; Evans, RD; Soto-Mota, A; Vansant, H, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (75.00)24.3611
2020's2 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (50.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies1 (12.50%)4.05%
Observational0 (0.00%)0.25%
Other2 (25.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetoacetic acid
acetoacetic acid : A 3-oxo monocarboxylic acid that is butyric acid bearing a 3-oxo substituent.		2.6103-oxo fatty acid;
ketone body		metabolite
3-hydroxybutyric acid
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.. 3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.		6.9741(omega-1)-hydroxy fatty acid;
3-hydroxy monocarboxylic acid;
hydroxybutyric acid		human metabolite
1,3-butylene glycol
1,3-butylene glycol: RN given refers to cpd without isomeric designation. butane-1,3-diol : A butanediol compound having two hydroxy groups in the 1- and 3-positions.		2.610butanediol;
glycol
acetoacetyl coa
[no description available]		3.5113-oxo-fatty acyl-CoAEscherichia coli metabolite;
mouse metabolite
glycogen
glycogen : A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues.		3.5311
mevalonic acid
Mevalonic Acid: A dihydroxy monocarboxylic acid and precursor in the biosynthetic pathway known as the mevalonate pathway, which produces terpenes and steroids that are vital for diverse cellular functions.. mevalonic acid : A racemate composed of equimolar amounts of (R)- and (S)-mevalonic acid.. (R)-mevalonic acid : The (R)-enantiomer of mevalonic acid.		3.5113,5-dihydroxy-3-methylpentanoic acid
3-hydroxy-3-methylglutaryl-coenzyme a
3-hydroxy-3-methylglutaryl-coenzyme A: RN given refers to cpd without isomeric designation. 3-hydroxy-3-methylglutaryl-CoA : An alpha,omega dicarboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of 3-hydroxy-3-methylglutaric acid.. (3S)-3-hydroxy-3-methylglutaryl-CoA : A 3-hydroxy-3-methylglutaryl-CoA where the 3-hydroxy-3-methylglutaryl component has (S)-configuration.		3.5113-hydroxy-3-methylglutaryl-CoA;
3-hydroxy fatty acyl-CoA		human metabolite;
mouse metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Chronic Illness
[description not available]		011.461616
Acetonemia
[description not available]		012.591816
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		011.461616
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		04.0810
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		04.0810
Hyperglycemia, Postprandial
Abnormally high BLOOD GLUCOSE level after a meal.		07.644
Insulin Sensitivity
[description not available]		07.644
Hyperglycemia
Abnormally high BLOOD GLUCOSE level.		07.644
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		07.644
Acute Confusional Senile Dementia
[description not available]		03.0310
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		03.0310